Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.65 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919695 | 0.90 | S1PR1 (0.75) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL1942995 | 0.88 | S1PR1 (0.59) | S1PR1S1PR4S1PR5ADORA3 | |
| SCHEMBL1918590 | 0.87 | S1PR1 (0.81) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL1920079 | 0.87 | S1PR1 (0.86) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL31198060 | 0.87 | S1PR1 (0.86) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL24176711 | 0.87 | S1PR1 (0.86) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL29886429 | 0.87 | S1PR1 (0.86) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL1941910 | 0.86 | S1PR1 (0.68) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL1919779 | 0.86 | S1PR1 (0.81) | S1PR1S1PR4S1PR5ADORA3 | |
| SCHEMBL1943776 | 0.86 | S1PR1 (0.84) | S1PR1S1PR4S1PR5ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20200407316-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2020-12-31 | — | — | US | disclosed |
| CN-104311472-B9 | Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives | 艾尼纳制药公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-104311472-B | Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives | 艾尼纳制药公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190135752-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20170217885-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9522133-B2 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2326621-B1 | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150335618-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9126932-B2 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140038987-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2014-02-06 | — | — | US | disclosed |
| US-8580841-B2 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110130409-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135752-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20110130409-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20170217885-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20200407316-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20140038987-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20150335618-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.